Northwell Health Converts BiPAP Machines Into Ventilators for Hospitalized COVID-19 Patients, Uses 3D Printed Adapter

To Prepare for Potential Surge of Coronavirus Patients in Need of Ventilators, Doctors and Engineers Designed 3D Printed Adaptor for use with a Common Breathing Machine

In preparation for potential patient surge and shortage of critical mechanical ventilators for hospitalized COVID-19 patients, a Northwell Health physician, a respiratory therapist, and a 3D printing bioengineer have successfully designed the protocol to turn the more common bi-level positive airway pressure (BiPAP) machine into a functional invasive mechanical ventilator, through a 3D printed adaptor they also designed to aid in the conversion.

BiPAP is one type of PAP, or positive airway pressure, non-invasive machine that is commonly used to maintain a consistent breathing pattern at night or during symptom flare-ups in people with sleep apnea, congestive heart failure or chronic obstructive pulmonary disease (COPD), a chronic inflammatory lung disease.

As the health systems nationwide brace themselves for a potential increase in COVID-19 patients and New York Governor Andrew Cuomo calls for an increased supply of ventilators for hospitals statewide, a team led by Hugh Cassiere, MD, medical director for respiratory therapy services at North Shore University Hospital (NSUH) and Stanley John, NSUH’s director of respiratory therapy, developed a method to convert the non-invasive Philips Respironics V60 BiPAP machine into a pressure-controlled ventilator for both patients with and without COVID-19 induced lung disease.

“Our hospitals are at the US epicenter of the coronavirus epidemic, and some of our COVID-19 patients require intensive care unit therapy and mechanical ventilators within minutes of being hospitalized,” said Dr. Cassiere. One sleepless night, Dr. Cassiere thought of the fleet of unused BiPAP machines in the hospitals. “I knew we could develop a way to repurpose and convert these machines to save hundreds of lives.”

Currently, Northwell Health has an adequate supply of ventilators for its patients, and the health system is continually trying to obtain more ventilators to prepare for a likely surge. And while there are plans in place to handle a surge in patient volume, Northwell Health has a good supply of BiPAP machines across its 23 hospitals, and if faced with a surge when ventilator numbers do get low, it would be helpful to use these machines.

The key component to converting the BiPAP machine is a small, plastic T-piece adapter. Because of COVID-19 related supply change shortages, Dr. Cassiere and Stanley John collaborated with Northwell Health’s 3D Design and Innovation department, and together they designed and 3D printed a T-piece in a matter of days.

“We were able to imitate the design of the T-piece adapter and print the plastic-resin piece with our 3D printers,” said Todd Goldstein, Ph.D., director of 3D Design and Innovation at Northwell Health. “If the need arises, we would be able to print 150 adaptors in 24-hours.”

In an effort to help other hospital systems across the nation, Northwell Health will share the new protocols to convert the BiPAP machine as well as share the T-adapter 3D print design online.

Drs. Cassiere, Goldstein, and Stanley John successfully tested the conversion of the BiPAP machine using the standard, non-3D printed adaptor for both COVID-19 and non-COVID-19 patients. They have also tested the 3D printed T-adaptor and have ramped up production to adopt the 3D printed adaptor clinically in the coming days.

In addition to the T-piece adaptor, modifications to the BiPAP machine include the addition of two high-efficiency particulate air (HEPA) filters at both ends of the oxygen hose to alleviate fears of spreading the virus. They are also recommending using a blind reservoir connected to the last HEPA filter in the circuit.

Last week, Northwell Health, with collaborators at the University of South Florida (USF) and Formlabs, a leading 3D printing company, announced they produced and tested a 3D printed nasal swab to address emergency shortages that hospitals and health care teams may face as testing for COVID-19 increases.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”